Press Releases

Date Title and Summary View
Toggle Summary Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor
--Enrollment target reached; topline data  on track for Q3 2018 announcement-- NEW YORK , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation,
View HTML
Toggle Summary Aquinox to Present at LEERINK Partners 7th Annual Global Healthcare Conference
VANCOUVER, British Columbia , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (“ Aquinox ”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today announced that
View HTML
Toggle Summary Aquinox to Host Analyst and Investor Event in New York City
External Expert, Management to Present on IC/BPS and Clinical Development Program VANCOUVER, British Columbia , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to
View HTML
Toggle Summary Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations
VANCOUVER, British Columbia , Dec. 15, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP) today announced that Lloyd Mackenzie has been promoted, effective immediately, to the newly created position of Chief Operating Officer and Vice President, R&D Operations.
View HTML
Toggle Summary Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
- Bone, Reproductive, and Urologic Drugs Advisory Committee Votes Unanimously in Favor of Unified IC/BPS Population for Clinical Trials - SILVER SPRING, Md. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company
View HTML
Toggle Summary Aquinox to Participate in 29th Annual Piper Jaffray Healthcare Conference
VANCOUVER, British Columbia , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results
VANCOUVER, British Columbia , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today reported financial results
View HTML
Toggle Summary Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
VANCOUVER, British Columbia , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
- Meeting to be Held December 7, 2017 - VANCOUVER, British Columbia , Aug. 28, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results
- Enrollment in LEADERSHIP 301 with Rosiptor in IC/BPS Passes 50% - - Selection of CP/CPPS as Second Clinical Indication - VANCOUVER, British Columbia , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering
View HTML